1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Amgen Inc.

Amgen Inc.

4332.HK
Amgen Inc.HK flagHong Kong Stock Exchange
1,850.00
HKD
- -
- -
998.46BMarket Cap
Amgen Inc.
4332.HK
(Hong Kong Stock Exchange)

Recent

price

1,850.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
15.68
17.22
22.28
24.8
26.43
28.58
30.74
31.26
35.93
38.61
43.39
45.58
48.93
52.69
62.24
68.31
69.05
Revenue per Share
4.82
4.07
5.61
6.75
6.8
9.15
10.32
2.71
12.7
12.96
12.4
10.34
12.18
12.56
7.62
14.33
14.47
Basic EPS, GAAP
5.42
5.03
6.67
7.43
10.47
11.98
12.72
14.38
15.97
14.1
16.88
14.7
16.33
13.76
19.36
15.06
15.95
Free Cash Flow per Basic Share
- -
0.55
1.44
1.88
2.44
3.16
4.01
4.6
5.31
5.8
6.41
7.04
7.8
8.52
9
9.52
9.65
Dividend per Share
24.78
20.84
24.41
29.56
33.97
37.68
40.57
35.46
20.07
16.86
17.74
13.15
7.23
12.19
11.07
16.57
17.4
Book Value per Share
10.81
5.19
3.14
-8.15
-2.24
2.18
6.48
2.56
-14.59
-40.4
-37.32
-41
-51.95
-84.18
-75.34
-60.03
-57.26
Tangible Book Value per Share
960
905
775
753
759
758
748
731
661
605
586
570
538
535
537
538
539
Basic Weighted Avg Shares
15,053
15,582
17,265
18,676
20,063
21,662
22,991
22,849
23,747
23,362
25,424
25,979
26,323
28,190
33,424
36,751
37,220
Sales/Revenue/Turnover
36.84
27.67
32.3
31.41
30.86
39.1
42.6
43.65
43.22
41.41
35.95
29.4
36.34
28.01
21.71
24.71
28.39
Operating Margin (%)
1,017
1,060
1,088
1,286
2,092
2,108
2,105
1,955
1,946
2,206
3,601
3,398
3,417
4,071
5,592
5,167
4,896
Depreciation Expense
4,627
3,683
4,345
5,081
5,158
6,939
7,722
1,979
8,394
7,842
7,264
5,893
6,552
6,717
4,090
7,711
7,800
Net Income, GAAP
12.98
11.25
13.26
3.49
7.65
13.02
15.73
79.38
12.06
14.18
10.68
12.06
10.81
14.49
11.26
14.09
14.16
Effective Tax Rate (%)
30.74
23.64
25.17
27.21
25.71
32.03
33.59
8.66
35.35
33.57
28.57
22.68
24.89
23.83
12.24
20.98
20.96
Profit Margin (%)
16,559
21,839
23,018
19,420
27,705
29,851
34,806
40,456
24,130
5,605
9,491
7,201
6,499
11,940
5,931
3,568
6,520
Working Capital
10,874
21,344
24,034
29,623
30,215
29,182
30,193
34,190
29,510
26,950
32,895
33,222
37,354
63,170
56,549
50,005
51,886
LT Debt
23,944
19,029
19,060
22,096
25,778
28,083
29,875
25,241
12,500
9,673
9,409
6,700
3,661
6,232
5,877
8,658
9,190
Total Equity
13.67
9.84
11.24
11.35
10.33
12.7
13.31
3.29
16.87
19.18
19.58
16.01
20.19
11.61
9.13
11.8
13.94
Return on Invested Capital (%)
14.64
10.91
12.27
12.16
11.09
13.55
14.06
3.56
17.74
20.5
20.1
16.5
18.67
16.1
10.05
15.56
15.49
Return on Capital (%)
19.94
17.27
23.01
24.68
21.47
25.53
26.22
7.03
42.84
66.83
70.54
65.88
115.07
129.01
65.63
103.79
98.62
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,153
4,599
5,437
LT Borrowings
52,434
50,005
51,886
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
538
539
540
Market Capitalization
127,767
127,935
127,167

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
27,885
29,057
31,475
Cash, Cash Equivalents & STI
9,445
9,129
12,038
Accounts Receivable, Net
8,490
9,570
9,138
Inventories
6,346
6,225
6,186
Total Current Liabilities
21,791
25,489
24,955
Payables & Accruals
19,638
19,453
19,518
ST Debt
2,153
4,599
5,437
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.73%
7.54%
47.32%
Free Cash Flow
0.49%
-1.5%
-22.07%
Net Income, GAAP
29.14%
8.85%
88.53%
Sales/Revenue/Turnover
5.58%
7.82%
9.95%
Total Cash Common Dividend
8.08%
6.42%
6.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,447
8,388
8,503
9,086
33,424
2025
8,149
9,179
9,557
9,866
36,751
2026
8,618
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.21
1.39
5.27
1.17
7.62
2025
3.22
2.66
- -
2.47
14.33
2026
3.37
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.25
2.25
2.25
2.24
9
2025
2.38
2.38
- -
2.38
9.52
2026
2.51
- -
- -
- -
- -
Similar Companies
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW)
Relief Therapeutics Holding AG (RLF.SW)
Frontage Holdings Corporation (FGHQF)
Sarepta Therapeutics, Inc. (0L35.L)
NeuroSense Therapeutics Ltd. (NRSNW)
Malachite Innovations, Inc. (VBIO)
Business
Amgen Inc. is a global biotechnology company that develops, manufactures, and markets human therapeutics across multiple biological pathways to address cancer, cardiovascular disease, inflammatory and autoimmune conditions, and other serious illnesses, with a broad portfolio of biologic and small-molecule medicines and related services. The firm maintains a diversified product line comprising therapeutic areas such as oncology, inflammation, nephrology, autoimmune disorders, and cardiovascular disease, supported by a robust pipeline and manufacturing network. Main products and services Amgen manufactures and sells a broad array of prescription medicines across major indications, including foundational biologics and innovative therapies. Core product categories include oncology and hematology therapies (eg, KYPROLIS for multiple myeloma, Vectibix for colorectal cancer, Blincyto for hematologic malignancies, and Tepmezza for thyroid-related conditions); inflammatory and autoimmune disease treatments (Enbrel for rheumatoid arthritis and other autoimmune diseases, Otezla for plaque psoriasis and psoriatic arthritis); cardiovascular and metabolic therapies (Repatha for hyperlipidemia and cardiovascular risk reduction); bone health products (Evenity for osteoporosis); anemia management (Aranesp); and other specialty medicines and biosystems. Amgen also engages in the development and commercialization of novel therapies through collaborations, licensing arrangements, and strategic partnerships, and it offers related supporting services including pharmacovigilance, medical information, patient assistance programs, and research collaboration opportunities. Latest major company changes Amgen expands manufacturing capacity and capability through significant capital investments, including expanding biopharmaceutical manufacturing facilities to increase production efficiency and supply resilience; it pursues strategic partnerships and collaborations to advance its oncology, inflammation, and cardiovascular pipelines, including licensing and co-development agreements; it advances pipeline milestones with regulatory submissions, clinical trial updates, and potential product line extensions; the company completes acquisitions or divestitures aligning with its strategic focus, and it engages in corporate reorganizations or structural adjustments to enhance operational efficiency and geographic reach; it announces new strategic initiatives around patient access, digital health integration, and manufacturing modernization, with ongoing efforts to diversify geographic manufacturing footprint and strengthen supply chain robustness. Additional context Amgen operates in multiple business segments aligned to product families, including Oncology/Hematology, Nephrology, Inflammation/Autoimmune Diseases, and Cardiovascular/Metabolic, with ancillary revenues from royalties and collaborations. Its geographic footprint spans North America, Europe, Asia-Pacific, Latin America, the Middle East, and other regions through subsidiaries and manufacturing sites, including major operations in the United States, Puerto Rico, Ireland, and Singapore, among others. The company’s corporate headquarters are located in Thousand Oaks, California, with a long-standing global distribution and commercial network. Amgen maintains a broad ecosystem of subsidiaries and partner relationships to support R&D, manufacturing, and commercialization. Note: Please verify current details from Amgen’s official materials and recent filings for the most up-to-date information on products, partnerships, investments, and organizational changes.